DAYANG BIOTECH(SZ:003017) Xin Lang Cai Jing·2025-08-26 02:45Core Insights - The company reported a total revenue of 499 million yuan for the first half of 2025, an increase of 62.09 million yuan compared to the same period last year, representing a year-on-year growth of 14.20% [1] - The net profit attributable to shareholders reached 50.51 million yuan, ranking 17th among disclosed peers, with a year-on-year increase of 60.66%, marking two consecutive years of growth [1] - The net cash inflow from operating activities was 113 million yuan, up by 79.62 million yuan from the same period last year, reflecting a significant year-on-year increase of 235.94% [1] Financial Ratios - The latest debt-to-asset ratio stands at 33.55%, ranking 14th among peers, down by 1.03 percentage points from the previous quarter and down by 3.49 percentage points year-on-year [3] - The latest gross profit margin is 24.31%, ranking 10th among peers, with a quarter-on-quarter increase of 1.15 percentage points and a year-on-year increase of 5.28 percentage points, achieving three consecutive years of growth [3] - The latest return on equity (ROE) is 4.67%, ranking 11th among peers, with a year-on-year increase of 1.56 percentage points [3] Earnings Per Share and Turnover Ratios - The diluted earnings per share (EPS) is 0.62 yuan, ranking 3rd among peers, with an increase of 0.24 yuan compared to the same period last year, representing a year-on-year growth of 61.06% [3] - The latest total asset turnover ratio is 0.30 times, ranking 19th among peers, with a year-on-year increase of 9.59% [3] - The latest inventory turnover ratio is 3.14 times, up by 0.74 times from the same period last year, reflecting a year-on-year increase of 31.11% [3] Shareholder Information - The number of shareholders is 14,200, with the top ten shareholders holding a total of 29.12 million shares, accounting for 34.67% of the total share capital [3] - The top shareholders include Chen Yanggui (8.86%), Yang Xingli (5.65%), and Wang Xianyue (4.80%) among others [3]